

Supplemental Table 26. Postprandial Changes in Paraoxonase Markers at the Beginning and at the End of the study

Intervention	Baseline (0h)	Change after intervention			P (trend) ^{a,b}
		2h	4h	6h	
<i>PON mass, mg/L</i>					
<i>Baseline</i>					
WFA (n=7)	155 (6.1)	18 (20)	43 (26)	6.8 (3.7)	0.125 ^a
AI (n=7)	172 (11)	-0.46 (6.8)	6.2 (7.0)[^]	8.9 (8.1)	0.225 ^b
RFA (n=10)	187 (13)	-11 (14)	-18 (9.9)[¥]	15 (18)	0.118 ^a
<i>6 weeks</i>					
WFA (n=7)	161 (7.5)	16 (22)	5.1 (15)	-13 (6.0)	0.175 ^b
AI (n=6)	223 (21)	-14 (24)	-12 (23)	-24 (20)	0.296 ^b
RFA (n=8)	177 (11)	32 (26)	26 (26)	37 (30)[^]	0.310 ^b
<i>PON raw (log), U/L</i>					
<i>Baseline</i>					
WFA (n=7)	2.31 (0.09)	-0.01 (0.03)	-0.003 (0.02)	-0.01 (0.01)	0.396 ^b

Table 2.15 (cont)

AI (n=7)	2.35 (0.10)	-0.003 (0.01)	-0.009 (0.01)	0.001 (0.02)	0.428 ^a
RFA (n=10)	2.33 (0.07)	0.01 (0.02)	-0.004 (0.01)	-0.006 (0.01)	0.339 ^b
<i>6 weeks</i>					
WFA (n=7)	2.25 (0.06)	0.01 (0.03)	-0.03(0.02)	0.01 (0.03)	0.152 ^b
AI (n=6)	2.35 (0.10)	-0.02 (0.02)	-0.03 (0.03)	-0.01 (0.01)	0.228 ^b
RFA (n=8)	2.34 (0.09)	-0.03 (0.04)	0.05 (0.09)	-0.009 (0.03)	0.609 ^b

PON specific (log), U/mg protein***Baseline***

WFA (n=7)	0.12 (0.09)	-0.05 (0.06)	-0.08 (0.06)	-0.03 (0.01)	0.112 ^b
AI (n=7)	0.12 (0.08)	0.001 (0.02)	-0.02(0.02)	-0.02(0.02)	0.295 ^b
RFA (n=10)	0.07 (0.06)	0.04 (0.03)	0.04 (0.02)[†]	-0.04 (0.02)	0.044^a

6 weeks

WFA (n=7)	0.04 (0.06)	-0.02 (0.07)	-0.04 (0.04)	0.05 (0.04)	0.127 ^a
-----------	-------------	--------------	--------------	-------------	--------------------

Table 2.15 (cont)

AI (n=6)	0.02 (0.10)	0.002 (0.06)	-0.005 (0.06)	0.03 (0.04)	0.493 ^b
RFA (n=8)	0.09 (0.09)	-0.09 (0.06)	0.03 (0.12)	-0.07 (0.06)	0.708 ^b

Arylesterase raw, U/L***Baseline***

WFA (n=7)	93 (10)	3.5 (13)	-4.3 (9.3)	-1.2 (7.4)	0.604 ^b
AI (n=7)	116 (9.3)	-0.40 (10)	-3.7 (9.9)	-2.0 (3.0)	0.339 ^b
RFA (n=10)	120 (9.3)	-9.5 (7.5)	-6.1 (6.9)	2.7 (3.4)	0.136 ^a

6 weeks

WFA (n=7)	96 (14)	1.4 (10)	-5.7 (6.7)	-0.41 (2.6)	0.335 ^b
AI (n=6)	116 (11)	-5.0 (7.4)	-0.88 (3.0)	-1.3 (4.9)	0.638 ^a
RFA (n=8)	108 (12)	0.15 (10)	4.7 (4.2)	2.4 (4.5)	0.394 ^b

Arylesterase specific, U/mg protein***Baseline***

Table 2.15 (cont)

WFA (n=7)	0.60 (0.07)	-0.02 (0.08)	-0.10 (0.08)	-0.03 (0.04)	0.431 ^b
AI (n=7)	0.69 (0.08)	-0.003 (0.07)	-0.06 (0.06)	-0.05 (0.02)	<i>0.088^b</i>
RFA (n=10)	0.67 (0.07)	-0.009 (0.08)	0.04 (0.06)[†]	-0.02 (0.07)	0.672 ^a
<i>6 weeks</i>					
WFA (n=7)	0.63 (0.11)	-0.06 (0.12)	-0.05 (0.08)	0.05 (0.04)	0.354 ^b
AI (n=6)	0.57 (0.11)	-0.03 (0.10)	0.02 (0.04)	0.06 (0.05)	0.231 ^b
RFA (n=8)	0.63 (0.07)	-0.07 (0.07)	0.03 (0.06)	-0.06 (0.08)	0.775 ^b

Data expressed as mean (standard error) in mmHg. Significant results in **bold** and borderline ones in ***italic bold***.

Intra-treatment comparison by General Linear Model with Bonferroni correction. P for: ^a quadratic trend; ^b linear trend. No inter-treatment changes were observed.

Inter-treatment comparisons by ANCOVA Model adjusted by age and sex. [^] P<0.07, [†] P<0.05; [‡] P<0.01 versus White Apple treatment; P<0.05